Zinbryta vs. Ocrevus

• Are Ocrevus and Zinbryta the Same Thing?
• What Are Possible Side Effects of Zinbryta?
• What Are Possible Side Effects of Ocrevus?
• What Is Zinbryta?
• What Is Ocrevus?
• What Drugs Interact with Zinbryta?
• What Drugs Interact with Ocrevus?
• How Should Zinbryta Be Taken?
• How Should Ocrevus Be Taken?

Zinbryta (daclizumab) injection and Ocrevus (ocrelizumab) injection are monoclonal antibodies used to treat patients with relapsing forms of multiple sclerosis (MS).

Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Ocrevus is also used to treat primary progressive forms of multiple sclerosis.

Zinbryta and Ocrevus are different types of monoclonal antibodies. Zinbryta is an interleukin-2 receptor blocking antibody and Ocrevus injection is aCD20-directed cytolytic antibody.

Side effects of Zinbryta and Ocrevus that are similar include upper respiratory tract infection, lower respiratory tract infections (such as bronchitis), and depression.

Side effects of Zinbryta that are different from Ocrevus include runny or stuffy nose, skin rash (including drug rash), influenza, mouth pain, sore throat, eczema, swollen lymph nodes, increased alanine aminotransferase (ALT), anemia, acne, and fever.

Side effects of Ocrevus that are different from Zinbryta include infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate), skin infections, back pain, and pain in the extremities.

Zinbryta may interact with drugs or herbal products that are toxic to the liver.

Ocrevus may interact with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids.

Common side effects of Zinbryta include:

• runny or stuffy nose
• upper respiratory tract infection
• rash, including drug rash
• influenza
• skin rash
• mouth pain
• sore throat
• bronchitis
• eczema
• swollen lymph nodes
• depression
• increased alanine aminotransferase (ALT)
• acne
• anemia, and
• fever

Less common side effects of Zinbryta include:

• abnormal liver function test,
• decreased lymphocyte count
• diarrhea
• dry skin
• skin redness
• hair bumps (folliculitis)
• increased liver enzymes
• laryngitis
• enlarged lymph nodes
• pneumonia
• itching
• psoriasis
• skin peeling
• toxic skin eruption, and
• viral infection

Common side effects of Ocrevus include:

• upper respiratory tract infections,
• infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate),
• skin infections,
• lower respiratory tract infections,
• depression,
• back pain, and
• pain in the extremities.

Zinbryta (daclizumab) injection is an interleukin-2 receptor blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Ocrevus (ocrelizumab) injection is aCD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.

Zinbryta may interact with hepatotoxic drugs or herbal products. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before taking Zinbryta. It is unknown if it would affect a fetus. It is unknown if Zinbryta passes into breast milk or if it would affect a nursing infant. Consult your doctor before breastfeeding.

Hepatitis B virus screening is required before the first dose of Ocrevus. Pre-medicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine prior to each infusion. The starting dose of Ocrevus is 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion. Subsequent doses of Ocrevus are 600 mg intravenous infusion every 6 months.

The recommended dosage of Zinbryta is 150 milligrams once monthly.

The recommended dosage of Ocrevus is 12 mg/day administered by intravenous infusion for 2 treatment courses: First Treatment Course: 12 mg/day on 5 consecutive days (60 mg total dose; Second Treatment Course: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the first treatment course.